In vivo assessment of pharmacokinetic interactions of empagliflozin and henagliflozin with sorafenib: an animal-based study
Background Sorafenib is a multi-targeted tyrosine kinase inhibitor (TKI) used for the treatment of advanced renal cell carcinoma, hepatocellular carcinoma (HCC), and radioactive iodine-resistant thyroid carcinoma. Notably, glucose transporters sodium-glucose cotransporter 2 (SGLT2) and glucose trans...
Saved in:
Main Authors: | , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
PeerJ Inc.
2025-07-01
|
Series: | PeerJ |
Subjects: | |
Online Access: | https://peerj.com/articles/19662.pdf |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|